MATRIX-COUPLED AUTOLOGOUS CHONDROCYTE-TRANSPLANTATION VERSUS MICROFRACTURING AS THERAPY OF JOINT CARTILAGE DEFECTS OF THE KNEE JOINT: MID-TERM RESULTS IN A 3-YEAR FOLLOW-UP

Abstract

Ouery: Matrix-coupled autologous chondrocyte transplantation (MACT) has become increasingly widespread in the therapy of cartilage defects. The objective of this controlled prospective study was to examine the mid-term results of MACT compared to those of Microfracturing (MF) for the treatment of cartilage defects in the knee joint and to determine possible advantages or disadvantages of the two methods.

Method: In order to compare the two treatment methods, 40 patients with discrete cartilage defects were treated with MACT and 40 with MF between 4/01 – 4/03. As inclusion criterion, the patients had a chondral defect of at least 1.5 cm and as exclusion criterion, there could be no additional cartilage damage in the other areas of the knee. MRI examinations were performed preoperative (T2 gew. TSE-Sequence, fetts. FLASH-3D) and could be repeated after 6 and 12 months. Knee joint function, the activity level and the patient’s quality of life were evaluated in both groups pre- and postoperative using the modified Cincinnati Score and the Tegner Activity Index.

Results: There was significant improvement in the scores used for the study in both the MF group and the MACT group. Comparison of the two groups revealed significantly greater clinical improvement in the MACT patients than in the MF patients (3.8 point increase MACT versus 2.6 point increase MF in the Cincinnati Score). Taking the size extent of the treated cartilage damage into account, there was, however, no relevant difference in defects less than 2,5 qcm.

Conclusion: The study could demonstrate that both methods are successful in treating localized cartilage damage in the knee joint. Comparison of the two forms of therapy showed a greater extent of improvement in the MACT group. However, classification by the size of the defect revealed that this effect was relevant only in larger defects, so that the size of the defect should be a decisive criterion for the selection of therapy.